0	3	The	the	DT
4	17	interleukin-8	interleukin-8	NN
18	22	AP-1	ap-1	NN
23	26	and	and	CC
27	32	kappa	kappa	NN
33	39	B-like	b-like	JJ
40	45	sites	site	NNS
46	49	are	be	VBP
50	57	genetic	genetic	JJ
58	61	end	end	NN
62	69	targets	target	NNS
70	72	of	of	IN
73	88	FK506-sensitive	fk506-sensitive	JJ
89	96	pathway	pathway	NN
97	108	accompanied	accompany	VBN
109	111	by	by	IN
112	119	calcium	calcium	NN
120	132	mobilization	mobilization	NN
132	133	.	.	.

135	140	FK506	FK506	NNP
140	141	,	,	,
142	144	an	an	DT
145	162	immunosuppressant	immunosuppressant	NN
162	163	,	,	,
164	172	inhibits	inhibit	VBZ
173	176	the	the	DT
177	187	production	production	NN
188	190	of	of	IN
191	198	several	several	JJ
199	208	cytokines	cytokine	NNS
209	211	in	in	IN
212	213	T	t	NN
214	225	lymphocytes	lymphocyte	NNS
225	226	.	.	.

227	229	We	we	PRP
230	238	observed	observe	VBD
239	243	that	that	IN
244	249	FK506	FK506	NNP
250	260	suppressed	suppress	VBD
261	264	the	the	DT
265	278	transcription	transcription	NN
279	281	of	of	IN
282	283	a	a	DT
284	295	chemotactic	chemotactic	JJ
296	304	cytokine	cytokine	NN
304	305	,	,	,
306	319	interleukin-8	interleukin-8	NN
320	321	(	(	(
321	325	IL-8	il-8	NN
325	326	)	)	)
327	329	in	in	IN
330	331	a	a	DT
332	337	human	human	JJ
338	339	T	t	NN
340	344	cell	cell	NN
345	349	line	line	NN
349	350	,	,	,
351	357	Jurkat	Jurkat	NNP
358	363	cells	cell	NNS
363	364	,	,	,
365	374	activated	activate	VBN
375	377	by	by	IN
378	385	phorbol	phorbol	NN
386	398	12-myristate	12-myristate	NN
399	409	13-acetate	13-acetate	NN
410	411	(	(	(
411	414	PMA	PMA	NNP
414	415	)	)	)
416	419	and	and	CC
420	427	calcium	calcium	NN
428	429	(	(	(
429	433	Ca2+	Ca2+	NNP
433	434	)	)	)
435	444	ionophore	ionophore	NN
445	446	(	(	(
446	455	ionomycin	ionomycin	NN
455	456	)	)	)
456	457	.	.	.

458	460	By	by	IN
461	468	deleted	delete	VBN
469	472	and	and	CC
473	480	mutated	mutate	VBN
481	489	analysis	analysis	NN
490	492	of	of	IN
493	496	the	the	DT
497	501	IL-8	il-8	NN
502	511	promoters	promoter	NNS
511	512	,	,	,
513	516	the	the	DT
517	521	AP-1	ap-1	NN
522	525	and	and	CC
526	531	kappa	kappa	NN
532	538	B-like	b-like	JJ
539	544	sites	site	NNS
545	549	were	be	VBD
550	560	identified	identify	VBN
561	563	as	as	IN
564	567	the	the	DT
568	578	responsive	responsive	JJ
579	587	elements	element	NNS
588	591	for	for	IN
592	595	PMA	PMA	NNP
596	599	and	and	CC
600	609	ionomycin	ionomycin	NN
609	610	.	.	.

611	616	FK506	FK506	NNP
617	627	suppressed	suppress	VBD
628	631	the	the	DT
632	646	transcriptions	transcription	NNS
647	654	through	through	IN
655	658	the	the	DT
659	663	AP-1	ap-1	NN
664	666	or	or	CC
667	672	kappa	kappa	NN
673	679	B-like	b-like	JJ
680	685	sites	site	NNS
686	693	induced	induce	VBN
694	696	by	by	IN
697	700	PMA	PMA	NNP
701	705	plus	plus	CC
706	723	Ca(2+)-mobilizing	ca(2+)-mobilizing	NN
724	730	agents	agent	NNS
730	731	,	,	,
732	735	but	but	CC
736	739	not	not	RB
740	745	those	those	DT
746	753	induced	induce	VBN
754	756	by	by	IN
757	775	Ca(2+)-independent	ca(2+)-independent	JJ
776	783	stimuli	stimulus	NNS
783	784	.	.	.

785	787	In	in	IN
788	791	gel	gel	NN
792	803	retardation	retardation	NN
804	812	analysis	analysis	NN
812	813	,	,	,
814	819	FK506	FK506	NNP
820	823	had	have	VBD
824	830	little	little	JJ
831	837	effect	effect	NN
838	840	on	on	IN
841	844	the	the	DT
845	852	binding	binding	NN
853	855	to	to	TO
856	859	the	the	DT
860	864	AP-1	ap-1	NN
865	869	site	site	NN
870	872	of	of	IN
873	894	PMA/ionomycin-induced	pma/ionomycin-induced	JJ
895	902	nuclear	nuclear	JJ
903	910	factors	factor	NNS
910	911	,	,	,
912	917	which	which	WDT
918	922	were	be	VBD
923	933	recognized	recognize	VBN
934	938	with	with	IN
939	948	anti-JunD	anti-jund	JJ
949	951	or	or	CC
952	957	c-Fos	c-fos	NN
958	966	antibody	antibody	NN
966	967	.	.	.

968	970	In	in	IN
971	979	contrast	contrast	NN
979	980	,	,	,
981	986	FK506	FK506	NNP
987	989	or	or	CC
990	994	EGTA	EGTA	NNP
995	996	(	(	(
996	1000	Ca2+	Ca2+	NNP
1001	1009	chelator	chelator	NN
1009	1010	)	)	)
1011	1020	similarly	similarly	RB
1021	1029	affected	affect	VBD
1030	1033	the	the	DT
1034	1043	formation	formation	NN
1044	1046	of	of	IN
1047	1052	kappa	kappa	NN
1053	1059	B-like	b-like	JJ
1060	1064	site	site	NN
1065	1072	binding	binding	NN
1073	1082	complexes	complex	NNS
1082	1083	,	,	,
1084	1089	which	which	WDT
1090	1094	were	be	VBD
1095	1098	not	not	RB
1099	1109	recognized	recognize	VBN
1110	1112	by	by	IN
1113	1116	any	any	DT
1117	1127	antibodies	antibody	NNS
1128	1135	against	against	IN
1136	1139	the	the	DT
1140	1145	human	human	JJ
1146	1149	Rel	Rel	NNP
1150	1156	family	family	NN
1157	1165	proteins	protein	NNS
1166	1167	(	(	(
1167	1172	c-Rel	c-rel	NN
1172	1173	,	,	,
1174	1177	p65	p65	NN
1177	1178	,	,	,
1179	1182	p50	p50	NN
1182	1183	,	,	,
1184	1187	and	and	CC
1188	1191	p49	p49	NN
1191	1192	)	)	)
1192	1193	.	.	.

1194	1205	Furthermore	furthermore	RB
1205	1206	,	,	,
1207	1209	we	we	PRP
1210	1219	confirmed	confirm	VBD
1220	1223	the	the	DT
1224	1232	previous	previous	JJ
1233	1239	report	report	NN
1240	1244	that	that	IN
1245	1250	FK506	FK506	NNP
1251	1261	suppressed	suppress	VBD
1262	1265	the	the	DT
1266	1287	PMA/ionomycin-induced	pma/ionomycin-induced	JJ
1288	1298	activation	activation	NN
1299	1306	through	through	IN
1307	1316	authentic	authentic	JJ
1317	1322	kappa	kappa	NN
1323	1324	B	B	NNP
1325	1329	site	site	NN
1330	1332	of	of	IN
1333	1347	immunoglobulin	immunoglobulin	NN
1348	1349	(	(	(
1349	1351	Ig	ig	NN
1351	1352	)	)	)
1353	1357	gene	gene	NN
1357	1358	,	,	,
1359	1361	to	to	TO
1362	1367	which	which	WDT
1368	1376	NF-kappa	NF-kappa	NNP
1377	1378	B	B	NNP
1379	1386	binding	binding	NN
1387	1390	was	be	VBD
1391	1395	also	also	RB
1396	1405	decreased	decrease	VBN
1406	1408	by	by	IN
1409	1414	FK506	FK506	NNP
1414	1415	,	,	,
1416	1426	indicating	indicate	VBG
1427	1431	that	that	IN
1432	1436	both	both	CC
1437	1441	IL-8	il-8	NN
1442	1447	kappa	kappa	NN
1448	1454	B-like	b-like	JJ
1455	1459	site	site	NN
1460	1463	and	and	CC
1464	1466	Ig	ig	NN
1467	1472	kappa	kappa	NN
1473	1474	B	B	NNP
1475	1479	site	site	NN
1480	1483	are	be	VBP
1484	1499	FK506-sensitive	fk506-sensitive	JJ
1500	1502	in	in	IN
1503	1508	spite	spite	NN
1509	1511	of	of	IN
1512	1515	the	the	DT
1516	1526	difference	difference	NN
1527	1529	of	of	IN
1530	1537	binding	bind	VBG
1538	1545	factors	factor	NNS
1545	1546	.	.	.

1547	1550	Our	our	PRP$
1551	1558	results	result	NNS
1559	1567	indicate	indicate	VBP
1568	1572	that	that	IN
1573	1576	not	not	RB
1577	1581	only	only	RB
1582	1585	the	the	DT
1586	1594	reported	report	VBN
1595	1599	IL-2	IL-2	NNP
1600	1605	NF-AT	NF-AT	NNP
1606	1609	and	and	CC
1610	1617	NFIL-2A	NFIL-2A	NNP
1618	1623	sites	site	NNS
1624	1627	and	and	CC
1628	1630	Ig	ig	NN
1631	1636	kappa	kappa	NN
1637	1638	B	B	NNP
1639	1643	site	site	NN
1643	1644	,	,	,
1645	1648	but	but	CC
1649	1653	also	also	RB
1654	1657	the	the	DT
1658	1662	IL-8	il-8	NN
1663	1667	AP-1	ap-1	NN
1668	1671	and	and	CC
1672	1677	kappa	kappa	NN
1678	1684	B-like	b-like	JJ
1685	1690	sites	site	NNS
1691	1694	are	be	VBP
1695	1704	terminals	terminal	NNS
1705	1707	of	of	IN
1708	1723	FK506-sensitive	fk506-sensitive	JJ
1724	1731	pathway	pathway	NN
1732	1741	involving	involve	VBG
1742	1746	Ca2+	ca2+	NN
1747	1759	mobilization	mobilization	NN
1759	1760	.	.	.